Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 3
1989 5
1990 8
1991 4
1992 4
1993 8
1994 9
1995 11
1996 25
1997 26
1998 22
1999 28
2000 22
2001 27
2002 47
2003 46
2004 51
2005 62
2006 59
2007 75
2008 64
2009 57
2010 67
2011 55
2012 93
2013 73
2014 72
2015 69
2016 67
2017 57
2018 46
2019 63
2020 51
2021 46
2022 33
2023 31
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

1,322 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Pharmacology of bicalutamide"
Page 1
Dihydrotestosterone-induced hair regrowth inhibition by activating androgen receptor in C57BL6 mice simulates androgenetic alopecia.
Fu D, Huang J, Li K, Chen Y, He Y, Sun Y, Guo Y, Du L, Qu Q, Miao Y, Hu Z. Fu D, et al. Biomed Pharmacother. 2021 May;137:111247. doi: 10.1016/j.biopha.2021.111247. Epub 2021 Jan 29. Biomed Pharmacother. 2021. PMID: 33517191 Free article.
These effects of DHT could be partly reversed by the AR antagonist bicalutamide. DHT had similar effects in an ex vivo model of hair loss. ...
These effects of DHT could be partly reversed by the AR antagonist bicalutamide. DHT had similar effects in an ex vivo model of hair …
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL. Tran C, et al. Science. 2009 May 8;324(5928):787-90. doi: 10.1126/science.1168175. Epub 2009 Apr 9. Science. 2009. PMID: 19359544 Free PMC article. Clinical Trial.
Both compounds bind to the androgen receptor with greater relative affinity than the clinically used antiandrogen bicalutamide, reduce the efficiency of its nuclear translocation, and impair both DNA binding to androgen response elements and recruitment of coactivators. .. …
Both compounds bind to the androgen receptor with greater relative affinity than the clinically used antiandrogen bicalutamide, reduc …
Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial.
Gu W, Han W, Luo H, Zhou F, He D, Ma L, Guo H, Liang C, Chong T, Jiang J, Chen Z, Wang Y, Zou Q, Tian Y, Xiao J, Huang J, Zhu S, Dong Q, Zhang X, Li H, Yang X, Chen C, Li J, Jin C, Zhang X, Ye D; CHART Investigators. Gu W, et al. Lancet Oncol. 2022 Oct;23(10):1249-1260. doi: 10.1016/S1470-2045(22)00507-1. Epub 2022 Sep 5. Lancet Oncol. 2022. PMID: 36075260 Clinical Trial.
In this study, we aimed to evaluate the efficacy and safety of rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy (ADT) for high-volume, metastatic, hormone-sensitive prostate cancer. ...Serious adverse events were reported in 90 (28%) of 32 …
In this study, we aimed to evaluate the efficacy and safety of rezvilutamide versus bicalutamide in combination with androgen-depriva …
Identification of bicalutamide resistance-related genes and prognosis prediction in patients with prostate cancer.
Li Y, Wang H, Pan Y, Wang S, Zhang Z, Zhou H, Xu M, Liu X. Li Y, et al. Front Endocrinol (Lausanne). 2023 Apr 18;14:1125299. doi: 10.3389/fendo.2023.1125299. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37143720 Free PMC article.
Therefore, this study aimed to identify hub genes related to bicalutamide resistance in PCa and provide new insights into endocrine therapy resistance. ...Weighted correlation network analysis was used to identify the gene modules related to bicalutamide resistance, …
Therefore, this study aimed to identify hub genes related to bicalutamide resistance in PCa and provide new insights into endocrine t …
An evaluation of bicalutamide in the treatment of prostate cancer.
Schellhammer PF. Schellhammer PF. Expert Opin Pharmacother. 2002 Sep;3(9):1313-28. doi: 10.1517/14656566.3.9.1313. Expert Opin Pharmacother. 2002. PMID: 12186624 Review.
The evidence reviewed demonstrates that bicalutamide currently has a favourable risk:benefit ratio in several stages of prostate cancer. The role of bicalutamide will be further defined by ongoing studies....
The evidence reviewed demonstrates that bicalutamide currently has a favourable risk:benefit ratio in several stages of prostate canc …
Mechanism of non-steroidal anti-androgen-induced liver injury: Reactive metabolites of flutamide and bicalutamide activate inflammasomes.
Kato R, Yamada T, Noda T, Tanaka S, Kohda Y, Ijiri Y. Kato R, et al. Toxicol In Vitro. 2023 Aug;90:105606. doi: 10.1016/j.tiv.2023.105606. Epub 2023 May 3. Toxicol In Vitro. 2023. PMID: 37146920
In the supernatant of FLC-4 cells with flutamide and bicalutamide, the heat shock protein (HSP) 40 or 60 was significantly increased. ...These results suggested that the reactive metabolites of flutamide and bicalutamide can cause the release of DAMPs from hepatocyt …
In the supernatant of FLC-4 cells with flutamide and bicalutamide, the heat shock protein (HSP) 40 or 60 was significantly increased. …
Treatment of bicalutamide-induced breast events.
Sieber PR. Sieber PR. Expert Rev Anticancer Ther. 2007 Dec;7(12):1773-9. doi: 10.1586/14737140.7.12.1773. Expert Rev Anticancer Ther. 2007. PMID: 18062751 Review.
Bicalutamide is a competitive nonsteroidal androgen receptor antagonist. ...The ongoing bicalutamide Early Prostate Cancer (EPC) program has shown that breast events, defined as gynecomastia, breast pain or both, are a significant limitation of bicalutamide. …
Bicalutamide is a competitive nonsteroidal androgen receptor antagonist. ...The ongoing bicalutamide Early Prostate Cancer (EP …
Bicalutamide 150mg: a review of its use in the treatment of locally advanced prostate cancer.
Wellington K, Keam SJ. Wellington K, et al. Drugs. 2006;66(6):837-50. doi: 10.2165/00003495-200666060-00007. Drugs. 2006. PMID: 16706554 Review.
Combined analysis of the three trials that comprise the bicalutamide Early Prostate Cancer (EPC) programme showed that bicalutamide administered in conjunction with standard care in men with locally advanced prostate cancer offers disease-free survival benefits over …
Combined analysis of the three trials that comprise the bicalutamide Early Prostate Cancer (EPC) programme showed that bicalutamid …
Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development.
Kolvenbag GJ, Blackledge GR, Gotting-Smith K. Kolvenbag GJ, et al. Prostate. 1998 Jan 1;34(1):61-72. doi: 10.1002/(sici)1097-0045(19980101)34:1<61::aid-pros8>3.0.co;2-n. Prostate. 1998. PMID: 9428389 Review.
RESULTS: In dose-ranging trials, bicalutamide doses of 10-200 elicited biochemical, objective, and subjective responses; higher bicalutamide doses (up to 600 mg) have also been evaluated. ...Bicalutamide is well tolerated when used as monotherapy or in combin …
RESULTS: In dose-ranging trials, bicalutamide doses of 10-200 elicited biochemical, objective, and subjective responses; higher bi …
Bicalutamide dosages used in the treatment of prostate cancer.
Kolvenbag GJ, Nash A. Kolvenbag GJ, et al. Prostate. 1999 Apr 1;39(1):47-53. doi: 10.1002/(sici)1097-0045(19990401)39:1<47::aid-pros8>3.0.co;2-x. Prostate. 1999. PMID: 10221266 Review.
Third, bicalutamide 50 mg has an excellent tolerability profile. Fourth, at the 50-mg dose, bicalutamide plus luteinizing hormone-releasing hormone analogue was equivalent to flutamide plus luteinizing hormone-releasing hormone analogue, although there was a trend t …
Third, bicalutamide 50 mg has an excellent tolerability profile. Fourth, at the 50-mg dose, bicalutamide plus luteinizing horm …
1,322 results